Safety and Immunogenicity Study of SeV-G(NP) HIV Vaccine Administered Intranasally and Ad35-GRIN HIV Vaccine Given Intramuscularly in Prime-Boost Regimens in HIV-Uninfected Volunteers

NCT01705990 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

65

Enrollment

NETWORK

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: SeV-G(NP) (0.2mL, 2x10^7 CIU)
BIOLOGICAL: SeV-G(NP) (0.2mL, 2x10^8 CIU)
BIOLOGICAL: Ad35-GRIN (0.5mL)

Sponsor

International AIDS Vaccine Initiative